期刊
CHEMISTRY & BIOLOGY
卷 22, 期 7, 页码 917-927出版社
CELL PRESS
DOI: 10.1016/j.chembiol.2015.05.016
关键词
-
资金
- European Community's Seventh Framework Program [260872]
- Slovak Research and Development Agency [DO7RP-0015-11]
- UK Medical Research Council [MC_UP_A253_1111]
- Wellcome Trust
- Bill and Melinda Gates Foundation [49852]
- FAPESP [2011/21232-1]
- CNPq [140079/2013-0]
- CAPES PDSE program [99999.003125/2014-09]
- Cancer Research UK
- MRC [MC_UP_A253_1111] Funding Source: UKRI
- Medical Research Council [MC_UP_A253_1111] Funding Source: researchfish
- The Francis Crick Institute [10060] Funding Source: researchfish
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [11/21232-1] Funding Source: FAPESP
To combat the emergence of drug-resistant strains of Mycobacterium tuberculosis, new antitubercular agents and novel drug targets are needed. Phenotypic screening of a library of 594 hit compounds uncovered two leads that were active against M. tuberculosis in its replicating, non-replicating, and intracellular states: compounds 7947882 (5-methyl-N-(4-nitrophenyl) thiophene-2-carboxamide) and 7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl) carba-mothioyl] propanamide). Mutants resistant to both compounds harbored mutations in ethA (rv3854c), the gene encoding the monooxygenase EthA, and/or in pyrG (rv1699) coding for the CTP synthetase, PyrG. Biochemical investigations demonstrated that EthA is responsible for the activation of the compounds, and by mass spectrometry we identified the active metabolite of 7947882, which directly inhibits PyrG activity. Metabolomic studies revealed that pharmacological inhibition of PyrG strongly perturbs DNA and RNA biosynthesis, and other metabolic processes requiring nucleotides. Finally, the crystal structure of PyrG was solved, paving the way for rational drug design with this newly validated drug target.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据